# A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

> **NCT00725855** · PHASE2 · UNKNOWN · sponsor: **Memory Pharmaceuticals** · enrollment: 12 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MEM 3454
- **DRUG:** MEM 3454
- **DRUG:** MEM 3454
- **DRUG:** MEM 3454
- **DRUG:** Placebo for MEM 3454

## Key facts

- **NCT ID:** NCT00725855
- **Lead sponsor:** Memory Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-08
- **Primary completion:** 2009-03
- **Final completion:** 2009-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2008-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725855, "A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00725855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*